nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver.

AIMS The nm23 gene has been shown to have metastasis suppressing activity and abnormalities of the gene or its expression may be important in tumour progression and dissemination. This study was set out to investigate the possible role of the nm23 in colorectal adenocarcinoma dissemination by examining the level of nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. METHODS Using a monoclonal antibody, NCL-nm23 (Novocastra), immunohistochemical expression of the nm23 protein was examined in cases of metastatic colorectal adenocarcinoma in regional lymph nodes (n=71) and liver (n=36). RESULTS The cases of lymph-node metastasis also had tissues from the primary carcinoma (n=71) and matching normal non-neoplastic mucosal tissues (n=71) from the colon and rectum available for the study. More than half of the cases of primary colorectal carcinoma (43/71; 60%) displayed strong nm23 immunoreactivity, with a similar proportion of the lymph-node metastases (40/71 cases; 56%) having strong nm23 immunostaining. However, only a small minority of the normal controls of non-neoplastic colorectal epithelia (12/71 cases; 17%) had strong nm23 immunoreactivity. The difference in nm23 protein expression between normal colorectal mucosa and primary colorectal carcinoma was statistically significant (P=0.0001; chi-squared test with continuity correction). However, no significant difference in nm23 protein expression was found between primary colorectal carcinoma and lymph-node metastases (P=0.81; chi-squared test with continuity correction). Most of the liver metastases (24/36 cases; 67%) had strong nm23 immunostaining but this finding was not statistically significant when compared with that seen in primary colorectal carcinoma (P=0.62; chi-squared test with continuity correction). In addition, nm23 expression was not found to significantly correlate with 5-year survival of patients with liver metastasis (P=0.86), suggesting that it had no predictive value for overall patient survival. There was also no significant correlation between disease recurrence and nm23 expression (P=0.63). CONCLUSIONS In summary, increased nm23 protein immunoreactivity is seen in the majority of colorectal carcinomas when compared to normal colorectal tissues but no significant difference in nm23 expression was found between primary colorectal carcinoma and metastatic carcinoma in regional lymph nodes or the liver. This study suggests that increased nm23 expression may be important in early colorectal carcinoma but not in later progression and dissemination of the tumour. In conclusion, the role and importance of the nm23 gene in the development of tumour metastasis in colorectal carcinoma is questionable.

[1]  K. Eu,et al.  NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas. , 1998, British Journal of Cancer.

[2]  K. Cohn,et al.  The significance of allelic deletions and aneuploidy in colorectal carcinoma , 1997, Cancer.

[3]  A. Vecchione,et al.  Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression. , 1997, Cancer letters.

[4]  G. Lindmark,et al.  NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. , 1996, British Journal of Cancer.

[5]  C. S. Lee,et al.  nm23‐H1 protein immunoreactivity in laryngeal carcinoma , 1996, Cancer.

[6]  R. Lamb,et al.  Allelic imbalance at NME1 in microdissected primary and metastatic human colorectal carcinomas is frequent but not associated with metastasis to lymph nodes or liver. , 1996, Cancer research.

[7]  B. Nordlinger,et al.  Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. , 1995, Gut.

[8]  P. Steeg,et al.  The potential roles of nm23 in cancer metastasis and cellular differentiation. , 1995, European journal of cancer.

[9]  Soon C. Lee,et al.  p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater , 1995, Pathology.

[10]  D. Huhn,et al.  Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. , 1994, British Journal of Cancer.

[11]  L. Cawkwell,et al.  Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. , 1994, British Journal of Cancer.

[12]  S. Cross,et al.  Nm23 ‘anti‐metastatic’ gene product expression in colorectal carcinoma , 1994, The Journal of pathology.

[13]  J. Northover,et al.  The Nm23 gene and colorectal cancer. , 1994, Gut.

[14]  W. Ichikawa.  Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.

[15]  T. Urano,et al.  Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. , 1993, British Journal of Cancer.

[16]  P. Steeg,et al.  Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. , 1993, Oncogene.

[17]  S. J. Flint,et al.  Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. , 1993, Science.

[18]  S. Banerjee,et al.  Mutation in the nm23 gene is associated with metastasis in colorectal cancer. , 1993, Cancer research.

[19]  L. Myeroff,et al.  Increased nm23-H1 and nm23-H2 messenger RNA expression and absence of mutations in colon carcinomas of low and high metastatic potential. , 1993, Journal of the National Cancer Institute.

[20]  O. Myklebost,et al.  Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. , 1992, Cancer research.

[21]  J. Thiery,et al.  Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. , 1991, European journal of cancer.

[22]  P. Steeg,et al.  Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma , 1991, The Lancet.

[23]  L. Liotta,et al.  Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. , 1991, The American journal of pathology.

[24]  J. Willson,et al.  Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential. , 1991, Journal of the National Cancer Institute.

[25]  L. Liotta,et al.  Somatic allelic deletion of nm23 in human cancer. , 1991, Cancer research.

[26]  L. Liotta,et al.  Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm3-transfected melanoma cells , 1991, Cell.

[27]  B Angus,et al.  Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. , 1991, Journal of the National Cancer Institute.

[28]  O. Bârzu,et al.  Dictyostelium Nucleoside Diphospate Kinase Highly Homologous to Nm23 and Awd Proteins Involved in Mammalian Tumor Metastasis and Drosphila Development , 1990 .

[29]  L. Liotta,et al.  Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development , 1989, Nature.

[30]  L. Liotta,et al.  Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. , 1989, Cancer research.

[31]  J. Overmeyer,et al.  Prevalence of nucleoside diphosphate kinase autophosphorylation in human colon carcinoma versus normal colon homogenates , 1989, Molecular carcinogenesis.

[32]  J E Talmadge,et al.  Evidence for a novel gene associated with low tumor metastatic potential. , 1988, Journal of the National Cancer Institute.